The Use of the Neuropsychiatric Inventory in Nursing Home Residents: Characterization and Measurement

Wood, Stacey; Cummings, Jeffrey L.; Hsu, Ming‐Ann; Barclay, Terry R.; Wheatley, Muriel Veen; Yarema, Kathryn T.; Schnelle, John F.

doi:10.1097/00019442-200002000-00010

Cited by 409 publications

(380 citation statements)

References 12 publications

Supporting

Mentioning

361

Contrasting

Order By: Relevance

“…Furthermore, post-synaptic expression of neurotransmitter receptors is equally important in the maintenance of synaptic transmission. For example, down-regulation of acetylcholine signaling in the hippocampal and cortical neuronal networks results in cognitive deficit, as observed during the progression of schizophrenia and Alzheimer's disease [71,72]. In Parkinson's disease, loss of dopaminergic neurons located in the substantia nigra, and the consequent interruption of neural transmission in the nigrostriatal pathway results in a substantial drop on dopamine bioavailability in the dorsal striatum (i.e., the caudate nucleus and putamen), and decreased activity of GABAergic neurons located in the striatum [73].…”

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

Neurophysiological Repercussions of Anabolic Steroid Abuse: A Road into Neurodegenerative Disorders

Seara¹,

Fortunato²,

Carvalho³

et al. 2018

Sex Hormones in Neurodegenerative Processes and Diseases

View full text Add to dashboard Cite

Since its discovery, several chemical modifications in the testosterone molecule have been done by pharmaceutical industry in order to improve its pharmacological effects, resulting in the creation of anabolic steroids (AS). Despite the therapeutic benefits, AS abuse has spread among elite and recreational athletes in the search for improvements on physical appearance and physical performance. Illicit use of anabolic AS has been correlated with several adverse effects, such as cardiovascular, endocrine, reproductive, and neurobehavioral dysfunctions. Recently, declines on cognitive and mnemonic performance have been demonstrated clinically and experimentally. Experimental studies have demonstrated that these neurological dysfunctions are correlated to spread neuronal apoptosis throughout important areas of the central nervous system (CNS), such as hippocampus and cortex. Several pathophysiological mechanisms have been linked to the AS-induced neurotoxicity, including redox imbalance and recruitment of pro-apoptotic downstream pathways. Furthermore, exposure to AS has arisen as a potential risk factor to the development of Alzheimer's disease. Altogether, these evidences imply that AS abuse per se induces neurodegeneration and can aggravate the prognosis of neurodegenerative diseases.

show abstract

Section: Neurodegenerative Diseasesmentioning

confidence: 99%

Neurophysiological Repercussions of Anabolic Steroid Abuse: A Road into Neurodegenerative Disorders

Seara¹,

Fortunato²,

Carvalho³

et al. 2018

Sex Hormones in Neurodegenerative Processes and Diseases

View full text Add to dashboard Cite

show abstract

“…The Neuropsychiatric Inventory (NPI) uses an informant interview to determine the presence of 12 common behavioral symptoms in dementia and includes frequency, severity, and level of distress to the caregiver [41]. A shortened version has been validated, and there have been modifications for use in a nursing home, self-completion by a caregiver, and recently, one by clinician assessment without caregiver interview [42][43][44]. The BEHAVE-AD scale is another well-validated tool which specifically targets the behavioral symptoms associated with AD [45,46].…”

Section: Assessment Toolsmentioning

confidence: 99%

Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias

Barton

Ketelle

Merrilees

et al. 2016

FOC

View full text Add to dashboard Cite

Worldwide prevalence of dementia is predicted to double every 20 years. The most common cause in individuals over 65 is Alzheimer's disease (AD), but in those under 65, frontotemporal dementia (FTD) is as frequent. The physical and cognitive decline that characterizes these diseases is commonly accompanied by troublesome behavioral symptoms. These behavioral symptoms contribute to significant morbidity and mortality among both patients and caregivers. Medications have been largely ineffective in managing these symptoms and carry significant adverse effects. Non-pharmacological interventions have been recommended to precede the utilization of pharmacological treatments. This article reviews the research about these interventions with special attention to the variations by etiology, especially FTD. The authors offer recommendations for improving utilization of these strategies and future research recommendations.

show abstract

“…We selected NPI as the main outcome measure because it is considered by many investigators as the standard method to measure BPSD. The NPI is an informant-based structured interview with acceptable psychometric properties (Cummings et al 1994;Cummings and Kaufer 1996;Wood et al 2000;Schneider et al 2001). Higher scores indicate higher frequency and severity of BPSD and a positive change from baseline refl ects worsening symptoms (Cummings et al 1994).…”

Section: Selection Criteriamentioning

confidence: 99%

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis

Campbell

Ayub

Boustani

et al. 2008

CIA

View full text Add to dashboard Cite

Objective: To determine the effi cacy of cholinesterase inhibitors (ChEIs) in improving the behavioral and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease (AD). Data sources: We searched MEDLINE, Cochrane Registry, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1966 to 2007. We limited our search to English Language, full text, published articles and human studies. Data extraction: We included randomized, double-blind, placebo-controlled trials evaluating the effi cacy of donepezil, rivastigmine, or galantamine in managing BPSD displayed by AD patients. Using the United States Preventive Services Task Force (USPSTF) guidelines, we critically appraised all studies and included only those with an attrition rate of less than 40%, concealed measurement of the outcomes, and intention to treat analysis of the collected data. All data were imputed into pre-defi ned evidence based tables and were pooled using the Review Manager 4.2.1 software for data synthesis. Results: We found 12 studies that met our inclusion criteria but only nine of them provided suffi cient data for the meta-analysis. Among patients with mild to severe AD and in comparison to placebo, ChEIs as a class had a benefi cial effects on reducing BPSD with a standard mean difference (SMD) of −0.10 (95% confi dence interval [CI]; −0.18, −0.01) and a weighted mean difference (WMD) of −1.38 neuropsychiatry inventory point (95% CI; −2.30, −0.46). In studies with mild AD patients, the WMD was −1.92 (95% CI; −3.18, −0.66); and in studies with severe AD patients, the WMD was −0.06 (95% CI; −2.12, +0.57). Conclusion: Cholinesterase inhibitors lead to a statistical signifi cant reduction in BPSD among patients with AD, yet the clinical relevance of this effect remains unclear.

show abstract

The Use of the Neuropsychiatric Inventory in Nursing Home Residents: Characterization and Measurement

Cited by 409 publications

References 12 publications

Neurophysiological Repercussions of Anabolic Steroid Abuse: A Road into Neurodegenerative Disorders

Neurophysiological Repercussions of Anabolic Steroid Abuse: A Road into Neurodegenerative Disorders

Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis

Contact Info

Product

Resources

About

The Use of the Neuropsychiatric Inventory in Nursing Home Residents: Characterization and Measurement

Cited by 409 publications

References 12 publications

Neurophysiological Repercussions of Anabolic Steroid Abuse: A Road into Neurodegenerative Disorders

Neurophysiological Repercussions of Anabolic Steroid Abuse: A Road into Neurodegenerative Disorders

Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer&rsquo;s disease: A meta-analysis

Contact Info

Product

Resources

About

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis